Swiss pharmaceutical giant Roche has had better sales than the company forecast in the first three months of the year, as diagnostics equipment and the hemophilia medicine Hemlibra in particular have sold surprisingly well, according to the firm's Q1 report.
Over the first quarter of the year, sales totaled CHF 14.93bn (USD 16.3bn), which slightly surpasses the analyst forecast of CHR 14.85bn.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.